Allogene Therapeutics

ALLO · NASDAQ

$1.33+$0.01 (+0.76%)TodayMarket closed · Oct 21, 4:25 AM ET

Prev close $1.32

ALLO analyst rating

BuyConsensus of 10 analysts over the last 12 months. 80% rate it a buy.

Strong buy0
Buy8
Hold2
Underperform0
Sell0

12-month price target · 11 analysts

Average $9.18 (+590.2% upside)

Low: $4.04
Now: $1.33
High: $14.70

Upgrades and downgrades

The latest rating actions, newest first

ALLO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Aug 17, 2026	Maintains	Market Outperform	$6.00	36%
JP Morgan	Apr 16, 2026	Upgrade	Underweight → Neutral	—	40%
HC Wainwright & Co.	Apr 16, 2026	Maintains	Buy	$12.00 → $11.00	41%
Jefferies	Apr 15, 2026	Maintains	Buy	$6.00 → $10.00	46%
Bernstein	Apr 14, 2026	Maintains	Market Perform	$1.60 → $3.85	52%
Argus Research	Apr 14, 2026	Maintains	Market Perform	$1.60 → $3.85	52%
Citizens	Apr 14, 2026	Maintains	Market Outperform	$5.00 → $8.00	36%
Baird	Apr 14, 2026	Maintains	Outperform	$7.00 → $9.00	33%
HC Wainwright & Co.	Apr 14, 2026	Maintains	Buy	$8.00 → $12.00	41%
Canaccord Genuity	Mar 13, 2026	Maintains	Buy	$14.00	35%

The case for and against

Updated Oct 7, 2026

Bull case

Allogene Therapeutics is supported by a compelling clinical pipeline, led by the ALPHA3 cema-cel program in LBCL, where interim MRD-negative rates of 58.3% versus 16.7% and a 41.6% delta signal meaningful activity alongside a clean safety profile with no CRS, ICANS, or GvHD. Management’s faster-than-expected site activation, already reaching the 80-site goal in July, and the company’s guidance for enrollment completion by YE2027 with an interim EFS analysis in mid-2027, improve visibility into value-driving catalysts. Its $423.6MM cash position and two assets in the clinic, including additional potential readouts over the next 6-12 months, provide financial runway and multiple shots at clinical success that underpin the positive outlook.

Bear case

Allogene Therapeutics is a clinical-stage cell therapy company facing substantial fundamental risk because its pipeline remains highly dependent on uncertain trial outcomes, regulatory approval, and manufacturing execution in a highly competitive CAR-T market. Despite $4.6MM in 2Q26 collaboration revenues and $423.6MM in cash, the company still posted an EPS loss of ($0.13), with R&D at $30.7MM and elevated SG&A of $20.8MM underscoring ongoing cash burn and limited operating leverage. The bearish view is further reinforced by the need for additional financing, partner dependence for key gene-editing technology, and the possibility that cema-cel and other assets fail to show sufficient efficacy or safety, which could materially undermine long-term value.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.